Risperidone long-acting injectable in the treatment of treatment-resistant schizophrenia with dopamine supersensitivity psychosis: Results of a 2-year prospective study,including an additional 1-year follow-up

Abstract

Dopamine supersensitivity psychosis (DSP) resulting from antipsychotic treatment is related to treatment-resistant schizophrenia (TRS), and its treatment has not been established to date. Maintaining thoroughly stable occupancy of the dopamine D2 receptor by risperidone long-acting injectable (RLAI) is one strategy for treatment. In this study, RLAI was given as an adjunctive medication to oral antipsychotic(s), which were switched partially and gradually to RLAI in 108 treatment-resistant patients for an additional 1-year follow-up in a 2-year study, and to compare the effects in 72 patients with a DSP history (DSP group) and 36 patients without this history (NonDSP group). Although both groups showed significant improvements in the total Brief Psychotic Rating Scale (BPRS) score during the follow-up period, greater improvement was observed for the DSP group than the NonDSP group. High doses (> 850 mg chlorpromazine-dose combined of oral antipsychotics and RLAI) did not significantly change in both groups throughout the study period; however, extrapyramidal symptoms, including tardive dyskinesia, were significantly improved only in the patients with DSP. This study strongly suggested that the RLAI treatment, even with only partial switching, provides relief from refractory symptoms, particularly for patients with a history of DSP.

Clinical trial registration: http://www.umin.ac.jp/:UMIN000008487

Keywords

Antipsychotic drugs dopamine dopamine D2 receptor dopamine sensitivity occupancy rate psychosis schizophrenia tardive dyskinesia tolerance treatment resistance

Get full access to this article

View all access options for this article.

References

Chouinard

(1991) Severe cases of neuroleptic-induced supersensitivity psychosis. Diagnostic criteria for the disorder and its treatment. Schizophr Res 5: 21–33.

Chouinard

Jones

(1980) Neuroleptic-induced supersensitivity psychosis: clinical and pharmacologic characteristics. Am J Psychiatry 137: 16–21.

Chouinard

Margolese

(2005) Manual for the Extrapyramidal Symptom Rating Scale (ESRS). Schizophr Res 76: 247–265.

Chouinard

Jones

Annable

(1978) Neuroleptic-induced supersensitivity psychosis. Am J Psychiatry 135: 1409–1410.

Eerdenkens

Hove

Remmerie

Mannaert

(2004) Pharmacokinetics and tolerability of long-acting risperidone in schizophrenia. Schizophr Res 70: 91–100.

Fallon

Dursun

(2011) A naturalistic controlled study of relapsing schizophrenic patients with tardive dyskinesia and supersensitivity psychosis. J Psychopharmacol 26: 755–762.

First

Spitzer

Gibbon

. (1995) Structured Clinical Interview for DSM-IV Axis I Disorders/Patient Edition (SCID-I/P, version 2.0). New York: New York State Psychiatric Institute.

Garfield

Clifford

Eliasson

. (2011) Suitability of measures of self-reported medication adherence for routine clinical use: A systematic review. BMC Med Res Methodol 11: 149.

Girardi

Serafini

Pompili

. (2010) Prospective, open study of long-acting injected risperidone versus oral antipsychotics in 88 chronically psychotic patients. Pharmacopsychiatry 43: 66–72.

10.

Gueorguieva

Krystal

(2004) Move over ANOVA: Progress in analyzing repeated-measures data and its reflection in papers published in the Archives of General Psychiatry. Arch Gen Psychiatry 61: 307–317.

11.

Huang

Ase

Hébert

Van Gelder

. (1997) Effects of chronic neuroleptic treatments on dopamine D1 and D2 receptors: Homogenate binding and autoradiographic studies. Neurochem Int 30: 277–290.

12.

Inoue

Miki

Seto

. (1997) Aripiprazole, a novel antipsychotic drug, inhibits quinpirole-evoked GTPase activity but does not up-regulate dopamine D2 receptor following repeated treatment in the rat striatum. Eur J Pharmacol 321: 105–111.

13.

Iyo

Tadokoro

Kanahara

. (2013) Optimal extent of dopamine D2 receptor occupancy by antipsychotics for treatment of dopamine supersensitivity psychosis and late-onset psychosis. J Clin Psychopharmacol 33: 398–404.

14.

Juarez-Reyes

Shumway

Battle

. (1995) Eligibility for clozapine among public mental health clients. Psychiatr Serv 46: 801–806.

15.

Kapur

Seeman

(2001) Does fast dissociation from the dopamine D2 receptor explain the action of antipsychotics? A new hypothesis. Am J Psychiatry 158: 360–369.

16.

Kazamatsuri

Chien

Cole

(1973) Long-term treatment of tardive dyskinesia with haloperidol and tetrabenazine. Am J Psychiatry 130: 479–483.

17.

Kimura

Kanahara

Komatus

. (2014) A prospective comparative study of risperidone long-acting injectable for treatment-resistant schizophrenia with dopamine supersensitivity psychosis. Schizophr Res 155: 52–58.

18.

Kimura

Kanahara

Watanabe

. (2013) Potential treatment strategy of risperidone long-acting injectable form for schizophrenia with dopamine supersensitivity psychosis. Schizophr Res 145: 130–131.

19.

Kirkpatrick

Alphs

Buchanan

(1992) The concept of supersensitivity psychosis. J Nerv Ment Dis 180: 265–270.

20.

Köhler

Schröder

Augusatin

. (1994) A new animal model of dopamine supersensitivity using s.c. implantation of haloperidol-releasing polymers. Neurosci Lett 170: 99–102.

21.

Louzã

Bassitt

(2005) Maintenance treatment of severe tardive dyskinesia with clozapine. 5 years’ follow-up. J Clin Psychopharmacol 25: 180–182.

22.

Moncrieff

(2006) Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid-onset psychosis (supersensitivity psychosis) and withdrawal-related relapse. Acta Psychiatr Scand 114: 3–13.

23.

Overall

Gorham

(1962) The brief psychiatric rating scale. Psychol Rep 10: 799–812.

24.

Samaha

Seeman

Stewart

. (2007) "Breakthrough" dopamine supersensitivity during ongoing antipsychotic treatment leads to treatment failure over time. J Neurosci 27: 2979–2986.

25.

Seeman

Tallerico

(1999) Rapid release of antipsychotic drugs from dopamine D2 receptors: An explanation for low receptor occupancy and early clinical relapse upon drug withdrawal of clozapine or quetiapine. Am J Psychiatry 156: 876–884.

26.

Silvestri

Seeman

Negrete

. (2000) Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: A clinical PET study. Psychopharmacology 152: 174–180.

27.

Suzuki

Kanahara

Yamanaka

. (2015) Dopamine supersensitivity psychosis as a pivotal factor in treatment-resistant schizophrenia. Psychiatr Res 227: 278–282.

28.

Takase

Kanahara

Oda

. (2015) Dopamine supersensitivity psychosis and dopamine partial agonist: A retrospective survey of failure of switching to aripiprazole in schizophrenia. J Psychopharmacology 29: 383–389.

29.

Vasconcelos

Nascimento

Nogueira

. (2003) Effects of haloperidol on rat behavior and density of dopaminergic D2-like receptors. Behav Processes 63: 45–52.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.05 MB